GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DBV Technologies SA (FRA:DBV1) » Definitions » Long-Term Capital Lease Obligation

DBV Technologies (FRA:DBV1) Long-Term Capital Lease Obligation : €6.04 Mil (As of Mar. 2025)


View and export this data going back to 2014. Start your Free Trial

What is DBV Technologies Long-Term Capital Lease Obligation?

DBV Technologies's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2025 was €6.04 Mil.

DBV Technologies's quarterly Long-Term Capital Lease Obligation declined from Sep. 2024 (€6.34 Mil) to Dec. 2024 (€6.01 Mil) but then increased from Dec. 2024 (€6.01 Mil) to Mar. 2025 (€6.04 Mil).

DBV Technologies's annual Long-Term Capital Lease Obligation increased from Dec. 2022 (€1.06 Mil) to Dec. 2023 (€4.15 Mil) and increased from Dec. 2023 (€4.15 Mil) to Dec. 2024 (€6.01 Mil).


DBV Technologies Long-Term Capital Lease Obligation Historical Data

The historical data trend for DBV Technologies's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DBV Technologies Long-Term Capital Lease Obligation Chart

DBV Technologies Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Long-Term Capital Lease Obligation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.63 6.33 1.06 4.15 6.01

DBV Technologies Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Long-Term Capital Lease Obligation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.25 6.30 6.34 6.01 6.04

DBV Technologies  (FRA:DBV1) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

DBV Technologies Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of DBV Technologies's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.


DBV Technologies Business Description

Industry
Traded in Other Exchanges
Address
107 Avenue de la Republique, Batiment IRO, Chatillon, Paris, FRA, 92320
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

DBV Technologies Headlines

No Headlines